CSIMarket Company Name, Ticker, Industry, else..
 
Ocular Therapeutix Inc   (NASDAQ: OCUL)
 
Price: $10.6400 $0.00 0.000%
Day's High: $10.770000457763672 Week Perf: 1.43 %
Day's Low: $ 10.51 30 Day Perf: 21.74 %
Volume (M): 1,306,354 52 Wk High: $ 16.44
Volume (M$): $ 0 52 Wk Avg: $10.32
Open: $10.51 52 Wk Low: $6.23



 Market Capitalization (Millions $) 2,384
 Shares Outstanding (Millions) 224
 Employees 325
 Revenues (TTM) (Millions $) 52
 Net Income (TTM) (Millions $) -291
 Cash Flow (TTM) (Millions $) 317
 Capital Exp. (TTM) (Millions $) 15

Business Description


Ocular Therapeutix Inc is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for diseases and conditions affecting the eye. They focus on creating sustained-release drug delivery systems to improve the effectiveness and convenience of eye treatments. Their products aim to address various ocular disorders such as glaucoma, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix aims to provide patients with long-lasting and efficient treatments that reduce the need for frequent medication administration.


   Company Address: 14 Crosby Drive, 3rd Floor Bedford 1730 MA
   Company Phone Number: 357-4000   Stock Exchange / Ticker: NASDAQ OCUL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.38% 
ARVN        2.29% 
BMY        0.36% 
EOLS        4.73% 
ONC   -2.31%    
REGN        4.22% 
• View Complete Report
   



Shares

Ocular Therapeutix Boosts Leadership with Strategic Inducement Awards to Drive Innovation and Shareholder Value,

Published Fri, Apr 11 2025 8:30 PM UTC

Ocular Therapeutix Strengthens Leadership Team with Strategic Inducement Awards to Propel Future GrowthBEDFORD, Mass. April 11, 2025 Ocular Therapeutix, Inc. (NASDAQ: OCUL), a leading biopharmaceutical firm at the forefront of ocular healthcare innovation, has announced the award of inducement stock incentives to Thomas J. Cella, the newly appointed Executive Director of P...
Shares

Visionary Moves: Ocular Therapeutix Harnesses Talent for Pioneering Eye Care Advances,

Published Fri, Dec 13 2024 12:00 PM UTC

Ocular Therapeutix s Strategic Inducements Fuel Pioneering Growth in Vision Care BEDFORD, Massachusetts In a bold move to bolster its leadership and expand its innovative capabilities in the ophthalmic field, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has recently announced a series of key inducement awards to new hires, aligning with its mission to enhance vision care acros...
Clinical Study

Ocular Therapeutix Hits Milestone with Over 300 Patients Enrolled in Pivotal SOL-1 Trial for AXPAXLI in Wet AMD...

Published Mon, Dec 2 2024 12:30 PM UTC

Ocular Therapeutix, Inc. a biotechnology company focused on developing innovative therapies for diseases and conditions of the eye, has made remarkable progress in its clinical trials for AXPAXLI, a promising investigational treatment for wet age-related macular degeneration (wet AMD). Recent announcements signify a significant milestone for the company as it has now randomi...
Management Announcement

Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise Enhancements

Published Tue, Oct 15 2024 11:31 AM UTC

Ocular Therapeutix Accelerates Wet AMD Trials Amid Strategic Expansion and Legal Expertise EnhancementsIn the dynamic landscape of biopharmaceutical innovation, Ocular Therapeutix, Inc. (NASDAQ: OCUL) has taken decisive steps towards solidifying its status as a pioneering leader in developing transformative therapies for retinal diseases and ocular conditions. Based in Bedfo...
Shares

Visionary Appointments: How Legal Expertise Catalyzes Ocular Therapeutix’s Growth,

Published Wed, Oct 9 2024 8:05 PM UTC

Unlocking Visionary Growth: Ocular Therapeutix s Strategic Inducement GrantIn the evolving sphere of biopharmaceutical companies, Ocular Therapeutix, Inc. (NASDAQ: OCUL) stands out as a trailblazer, pioneering innovative therapies for retinal diseases and various eye conditions. The Bedford, Massachusetts-based firm is not only committed to improving vision but is also visio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 45.82
Price to Sales (Expected) -
Price to Book 4.1
PEG (TTM) -

Financial Strength Current
Quick Ratio 14.98
Working Capital Ratio 15.86
Leverage Ratio (MRQ) 0.26
Total Debt to Equity 0.12
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.52 $
Revenues (TTM) 0.23 $
Cash Flow (TTM) 1.41 $
Cash 2.98 $
Book Value 2.6 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 160,117
Net Income per Employee (TTM) -893,840
Receivable Turnover Ratio (TTM) 1.79
Inventory Turnover Ratio (TTM) 1.92
Asset Turnover Ratio (TTM) 0.09

Profitability Ratios Current
Gross Margin (MRQ) 87.68 %
Operating Margin (MRQ) -865.46 %
Net Margin (MRQ) -821.62 %
Net Cash Flow Margin (MRQ) -652.4 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Ocular Therapeutix Inc's Segments
Single reportable segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.